The FDA has approved Eli Lilly’s Zepbound for treating obstructive sleep apnea, marking the first drug specifically for this common sleep disorder. Zepbound, containing tirzepatide, a GLP-1 agonist, showed significant effectiveness in clinical trials and could significantly impact the market, given the billions affected by sleep apnea. This approval positions Lilly competitively against other pharmaceutical companies developing similar treatments.
Eli Lilly’s stock price jumped after the Biden administration proposed expanding Medicare and Medicaid coverage for anti-obesity medications, potentially boosting sales of drugs like Mounjaro and Zepbound. The move aims to reduce healthcare costs and combat obesity.
US stock markets closed Wednesday with a mixed performance. The Dow Jones Industrial Average edged up slightly, while the NASDAQ and S&P 500 dipped. Eli Lilly’s disappointing earnings report weighed on the tech sector. Meanwhile, communication services performed strongly, driven by positive news from various companies.
Eli Lilly and Company (LLY) stock plummeted on Wednesday after the pharmaceutical giant reported weaker-than-expected third-quarter earnings and slashed its 2024 guidance. The company attributed the decline to increased research and development (R&D) costs and a decline in Trulicity sales. Despite a 20% year-over-year revenue increase, the company missed analysts’ expectations, leading to a significant drop in its stock price.
Eli Lilly, a major player in the weight loss drug market, is poised for a strong third-quarter earnings report, with Wall Street analysts expecting impressive revenue and earnings per share. The company’s stock has skyrocketed in recent months, leading to speculation about a potential stock split to make shares more accessible to investors.
Eli Lilly and Company (LLY) announced positive results from its TRAILBLAZER-ALZ 6 study, demonstrating a significant reduction in ARIA-E, a side effect associated with Alzheimer’s treatments, in patients receiving a modified dosing regimen of donanemab. The study revealed a 41% lower relative risk of ARIA-E in the modified group compared to standard dosing, with the most notable reduction seen in patients carrying the APOE4 gene, a known risk factor for Alzheimer’s.
Eli Lilly and Company (LLY) is set to release its third-quarter earnings on Wednesday, with Wall Street expecting strong performance driven by the company’s successful weight loss drugs. While the stock has experienced significant growth, technical indicators currently suggest a bearish outlook. However, analyst ratings and potential oversold status point towards a possible bullish recovery. This article analyzes the company’s earnings expectations, technical analysis, and analyst sentiments to provide a comprehensive outlook on Eli Lilly’s stock performance.
Eli Lilly and Company announced positive results from two Phase 3 studies of mirikizumab, showcasing its potential for sustained remission in both ulcerative colitis and Crohn’s disease. These findings, presented at the American College of Gastroenterology Annual Meeting, highlight the drug’s potential as a long-term treatment option for patients with inflammatory bowel diseases (IBDs).
Eli Lilly’s new eczema treatment, Ebglyss (lebrikizumab), has shown positive results in a Phase 3b study, demonstrating its effectiveness in improving skin and itch symptoms for patients with moderate-to-severe atopic dermatitis who previously received treatment with Dupixent. The study highlights Ebglyss’s potential as a viable alternative for individuals who didn’t achieve adequate control with Dupixent.
Eli Lilly has filed lawsuits against medical spas and online vendors for allegedly selling unauthorized versions of tirzepatide, the active ingredient in its weight-loss medication, Zepbound. This action comes despite the recent resolution of the FDA-declared tirzepatide injection shortage. Eli Lilly argues that these vendors are offering counterfeit products without FDA approval and are engaging in misleading advertising practices.
